N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine (MBDB): its properties and possible risks.
Addiction biology July 1, 2000 L A Aerts, M Mallaret, H Rigter 12 citations
MBDB, the alpha-ethyl homologue of MDMA, increases serotonin release and inhibits serotonin and noradrenaline re-uptake in the rat brain, though MDMA is more potent. MBDB may slightly increase dopamine release and inhibit its re-uptake, but to a lesser extent than MDMA. Its neuroendocrine effects resemble those of MDMA, raising plasma ACTH, corticosterone, prolactin, and renin. Neurophysiologically, MBDB decreases electrical activity across the brain, especially in alpha 2 and delta bands, unlike hallucinogens which increase alpha 1 activity. In humans, MBDB induces a pleasant introspective state with facilitated communication and empathy, but with slower onset, less euphoria, and fewer stimulant properties than MDMA.